Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 128 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2016', provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy
- The report reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chemotherapy Induced Peripheral Neuropathy therapeutics and enlists all their major and minor projects
- The report assesses Chemotherapy Induced Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chemotherapy Induced Peripheral Neuropathy Overview 10
Therapeutics Development 11
Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Overview 11
Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis 12
Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Development by Companies 13
Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 15
Chemotherapy Induced Peripheral Neuropathy - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Chemotherapy Induced Peripheral Neuropathy - Products under Development by Companies 19
Chemotherapy Induced Peripheral Neuropathy - Products under Investigation by Universities/Institutes 21
Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development 22
Achelios Therapeutics, Inc. 22
Advinus Therapeutics Ltd 23
Amplyx Pharmaceuticals, Inc. 24
Can-Fite BioPharma Ltd. 25
DermaXon, LLC 26
Eisai Co., Ltd. 27
Immune Pharmaceuticals Inc. 28
INSYS Therapeutics, Inc. 29
KPI Therapeutics, Inc. 30
Krenitsky Pharmaceuticals Inc. 31
Laboratorios Del Dr. Esteve S.A. 32
Lpath, Inc. 33
MAKScientific, LLC 34
Metys Pharmaceuticals AG 35
Midatech Pharma US Inc. 36
Nemus Bioscience, Inc. 37
Neurocentrx Pharma Ltd. 38
Panacea Pharmaceuticals, Inc. 39
PeriphaGen, Inc. 40
PharmatrophiX, Inc. 41
PledPharma AB 42
Sova Pharmaceuticals, Inc. 43
Spectrum Pharmaceuticals, Inc. 44
Virobay Inc. 45
WEX Pharmaceuticals Inc. 46
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Target 49
Assessment by Mechanism of Action 52
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 59
(amitriptyline + ketamine hydrochloride) - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
AM-1710 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
AXPN-02 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
BR-297 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
cannabidiol - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
dimiracetam - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Drugs for Peripheral Neuropathy - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
DX-0332 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
E-2072 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
HM-01 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
ketoprofen - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
KP-544 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
KRN-5500 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
LM11A-31BHS - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Lpathomab - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
MR-309 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
NB-2111 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
NRX-2922 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
NT-24336 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
PAN-811 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
PGN-503 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
piclidenoson - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
pirenzepine hydrochloride - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
PP-095 - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
Q-201 - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
Small Molecule for Pain - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
Small Molecule to Inhibit Cystathionine Gamma Lyase for Inflammatory Pain and Chemotherapy Induced Peripheral Neuropathy - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
Small Molecules to Inhibit FKBP52 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
SPI-205 - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
Tetrodotoxin - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
U-2902 - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
VBY-036 - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
XT-150 - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects 120
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products 121
Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones 122
Featured News & Press Releases 122
Jun 02, 2016: NEMUS Bioscience Identifies Unique Cannabidiol Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program 122
Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA 122
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 123
Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA 124
Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation 124
Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development 125
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 127
Disclaimer 128

List of Tables

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2016 11
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Comparative Analysis by Unknown Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics, Inc., H2 2016 22
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Advinus Therapeutics Ltd, H2 2016 23
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2016 24
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Can-Fite BioPharma Ltd., H2 2016 25
Chemotherapy Induced Peripheral Neuropathy - Pipeline by DermaXon, LLC, H2 2016 26
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co., Ltd., H2 2016 27
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc., H2 2016 28
Chemotherapy Induced Peripheral Neuropathy - Pipeline by INSYS Therapeutics, Inc., H2 2016 29
Chemotherapy Induced Peripheral Neuropathy - Pipeline by KPI Therapeutics, Inc., H2 2016 30
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016 31
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016 32
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Lpath, Inc., H2 2016 33
Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific, LLC, H2 2016 34
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Metys Pharmaceuticals AG, H2 2016 35
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Midatech Pharma US Inc., H2 2016 36
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience, Inc., H2 2016 37
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Neurocentrx Pharma Ltd., H2 2016 38
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals, Inc., H2 2016 39
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen, Inc., H2 2016 40
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX, Inc., H2 2016 41
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H2 2016 42
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals, Inc., H2 2016 43
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 44
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Virobay Inc., H2 2016 45
Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc., H2 2016 46
Assessment by Monotherapy Products, H2 2016 47
Assessment by Combination Products, H2 2016 48
Number of Products by Stage and Target, H2 2016 50
Number of Products by Stage and Mechanism of Action, H2 2016 53
Number of Products by Stage and Route of Administration, H2 2016 56
Number of Products by Stage and Molecule Type, H2 2016 58
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2016 120
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H2 2016 121